// App-Quantinova.ai

1004 : Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

Researchers

Presenter

  • Geoffrey J Lindeman

Principal Investigators

  • Rebecca Bowen

  • Katarzyna Joanna Jerzak

  • Xinni Song

  • Thomas Decker

  • Frances M. Boyle

  • Steven L. McCune

  • Anne Armstrong

  • Catherine M. Shannon

  • Gianfilippo Bertelli

  • Tharu M Fernando

  • Rupal Desai

  • Kushagra Gupta

  • Jerry Y. Hsu

  • Aulde Flechais

  • Aditya Bardia

Medical Centers

  • Peter MacCallum Cancer Centre/Walter and Eliza Hall Institute, Melbourne, Australia

  • Royal United Hospital NHS Foundation Trust, Bath, United Kingdom,

  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Canada.

  • Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, ON, Canada

  • Onkologie Ravensburg, Ravensburg, Germany

  • The Mater Hospital, Sydney, Australia

  • WellStar Health System, Marietta, GA

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Mater Cancer Care Centre, South Brisbane, QLD, Australia

  • Royal Sussex County Hospital, Brighton, United Kingdom

  • Genentech, Inc., South San Francisico, CA

  • IQVIA RDS, Inc., Pune, India

  • Genentech, San Francisco, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Massachusetts General Hospital Cancer Center, Boston, MA

Locations

  • Australia

  • United Kingdom

  • Canada

  • United States

  • Germany

  • India

  • Switzerland

Companies

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • B-cell lymphoma 2

  • Cyclin-dependent kinase 4

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Fulvestrant

  • Venetoclax

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT03584009

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved